معرفی
Professor Andrew Rowland is a leading academic at Flinders University's College of Medicine and Public Health. His research focuses on clinical pharmacology, particularly the impact of life stages, environmental factors, and diseases on drug exposure and response. He pioneers extracellular vesicle (EVs) isolation and analysis platforms for human biospecimens, collaborating with industry and clinicians to enhance drug efficacy and patient outcomes.
- PhD in Clinical Pharmacology, Flinders University (2009)
- BSc Hons in Pharmacology, Flinders University (2004)
His work intersects pharmacology, precision medicine, and drug metabolism, with recent projects targeting tissue-specific EVs in blood. Professor Rowland has secured over $8 million in competitive grants, including partnerships with Boehringer Ingelheim, AstraZeneca, and Pfizer.
Scientific recognition includes:
- British Journal of Clinical Pharmacology publication award (2019)
- Certara awards for impactful research (2019, 2017)
- Flinders University Vice Chancellor's Early Career Award (2013)
He actively mentors postgraduate students (Honours, PhD, MD) and teaches pharmacology to medical professionals, including doctors, paramedics, and nurse prescribers. His leadership extends to roles on the ASCEPT Board of Directors and editorial boards for journals like Therapeutic Advances in Drug Safety.
